Preliminary Results

16th Jun 2009 16:15



For immediate release 16 June 2009 

REGEN THERAPEUTICS PLC

Chairman's Statement and Preliminary Unaudited Results for the year ended 31 December 2008

PRELIMINARY STATEMENT 

Highlights of 2008

Colostrinin™ sales up 44%. Worldwide roll-out proceeds.

ReGen Therapeutics Plc ("ReGen" or "the Company" or "the Group") reacted quickly to the financial crisis, which engulfed the World in 2008. The Directors realised that as a small company, mainly dependent upon the capital markets in the unfashionable biotechnology sector, it was particularly vulnerable to the freezing of liquidity. The Directors therefore took every step to cut costs and focus on the commercial development of Colostrinin™ so that the Company would be able to fund itself as quickly as possible.

The commercialisation of Colostrinin™, further described below, means that the Company will achieve earlier profitability than was formerly the case. We also achieved a number of significant scientific milestones, which we also detail later in this statement.

Financials

Colostrinin™ sales rose 44% in 2008 to £91,982. Whilst these sales were over a full year for Metagenics in the USA, Canada and Australia the 2007 figures had been boosted by inventory building.

Research and Development costs fell during the year by £472,029 (59%) to £330,274. This reflected a number of items:

The largest fall was in the development cost of zolpidem, which finished its programme in 2008. Having reached a cost peak, including a successful clinical trial in 2007, zolpidem costs fell by £210,831 (45% of the total reduction). Whilst this project is now available for licensing to third parties we are pursuing external sources of funding which should give a chance of securing an enhanced licensing deal at no further cost to shareholders.

The veterinary work on Colostrinin™ came to an end at the start of 2008 and costs in this area fell by £79,900 (17% of the total). We are attempting to license out the project and no further development work is planned.

Nutraceutical Colostrinin™ is now in the roll out stage so costs here have dramatically reduced. Pharmacology and toxicology fell from £88,812 to £892. Licensing expenditure was reduced by £25,812 as we took the commercial development in house.

Colostrinin™ peptide research was also reduced by £45,803 as part of the Company's attempt to conserve cash. We did, however, complete the next stage of the Company's research programme. The results are now being evaluated by two global companies. We may, therefore, enter into a co-development partnership or licensing deal, which would enhance shareholder value.

Other administration costs from continuing operations also showed a fall of 18% as we kept careful control of expenses. This figure, however, understates the fall in cash expenditure, as there was an increase in the amortisation of patents of £263,346, a non-cash item. Thus, taking this into account and changes in depreciation cash expenditure for continuing operations was just £994,542 of which staff costs were £458,705 (46% of total). These costs were down 32% on the previous period and in view of the actions taken during the year staff costs will approximately halve in 2009. Thus, the loss before taxation for continuing activities fell by 42% to £1.510m. 

Turning now to the Balance Sheet the deterioration in cash and cash equivalents of £563,873 is the result of the freezing of the capital markets, which meant that ReGen raised only £677,138 of new capital in 2008 compared to £2,486,875 in 2007. The Company had to react by savagely cutting costs, utilizing the cash balances available, and extending its terms of trade where possible. This meant that Directors' salaries were halved, cash balances fell by £562,680, trade and other payables rose 57% (£178,063). During 2009 the Company has raised £367,000 so we believe that this deterioration has ceased and to some extent reversed.

Commercial development

Colostrinin™ roll out accelerates:

The roll out of Colostrinin™ as a nutraceutical, which has been developed to support healthy brain ageing and cognition is continuing in line with the Company's expectations.

The product is being sold (under the brand name CogniSure™) via healthcare professionals in the US, Canada and Australia through Metagenics, ReGen's licensing partner for those territories. Retail opportunities in the US market are being actively pursued.

At the beginning of March 2008, the Company announced its first European Union distribution agreement for Colostrinin™ with Golgi Pharmaceuticals Ltd of Cyprus and the launch of the nutraceutical product, under the brand name Cognase™, took place in October 2008.

The agreement with Golgi was extended on 25 March 2009 to allow them to distribute Colostrinin™ in Greece and other Balkan countries. On the same day a further agreement was signed with Golgi for them to tablet and package Colostrinin™ in the Republic of Cyprus. As part of this arrangement Golgi has directly invested £28,000 in cash into ReGen in exchange for 700,000 shares priced at 4p per share. This represented at the time 3.4% of the enlarged share capital of the Company and was a 33% premium to the previous placing on 2 March 2009.

On 26 November 2008 ReGen signed an agreement with Tagerr for the test marketing of Colostrinin™ in Poland. Tagerr is a professional services and trading company established in Cologne, Germany. In operation since 1995, Tagerr has enjoyed a number of successes in the marketing and distribution of consumer products including food supplements in Central Europe and Germany. In April 2009 it gained approval to import and market Colostrinin™ in Poland.

On 29 January 2009 ReGen signed an agreement with Eczacibasi Ilac Pazarlama A.S., a leading Turkish industrials group, as the exclusive distributor of its nutraceutical product Colostrinin™ in the Republic of Turkey.

This appointment is conditional upon Eczacibasi securing import and regulatory approval for the product. Should approval be forthcoming Eczacibasi will pay ReGen a $50,000 milestone payment on approval being granted and then a fee per unit for the active ingredient component of the formulated product. Net Revenues to ReGen from Eczacibasi pursuant to the minimum annual purchase commitments in the distribution agreement are estimated to be $52,000 in the first year after regulatory approval is obtained, and $104,000 in the second year.

Whilst the main Colostrinin™ "use" patent expires in October 2016, we are pleased to announce that the EU patent, which protects our manufacturing process, has been granted and this expires in March 2024. The manufacture of Colostrinin™ is proprietary and complex so that this patent grant is of considerable commercial significance.

Scientific development

Alzheimer's Conference on 17th September, 2008:

Professor Marian Kruzel, the Company's Chief Scientific Advisor presented a poster reviewing how Colostrinin™ achieves its clinical effect at the first Clinical Trials in Alzheimer's Disease Conference, held in Montpellier, France, 17th September, 2008.

Summarising the contents of his poster, Professor Kruzel said: 

"In this presentation I explained how such a low dose of Colostrinin™ can produce significant medical benefits in AD patients. I focussed on our findings from recent genomic microarray work, which shows that Colostrinin™ can favourably modulate the expression of several molecules involved in the pathology of Alzheimer's disease (upregulation of bleomycin hydrolase, downregulation of APP and effect on Tau phosphorylation). This enables the body's own multiple responses to reduce neuronal pathology and achieve homeostasis. The effect on Tau is said to be the reason for the response witnessed by the patients taking the drug Rember - product/trademark of TauRx. This data suggests that Colostrinin™, may be one of the first compounds with the potential to impact both Tau tangles and beta amyloid plaques, the two key pathologies of Alzheimer's disease."

Peer-reviewed International Immunopharmacology Journal

On the 4th December 2008 the full results of the genomic microarray study were published on line ahead of availability in print by the peer-reviewed journal International Immunopharmacology.

We emphasise two key points of the article. Firstly, Colostrinin™ can favourably modulate the expression of several molecules involved in the pathology of Alzheimer's disease - upregulation of bleomycin hydrolase, downregulation of APP and effect on Tau phosphorylation. Given that Alzheimer's is a complex disease the multi-faceted action shown by Colostrinin™ is significant. Secondly, Colostrinin™ also modulates other molecules involved in biological pathways associated with other conditions such as obesity and allergy.

For a long time ReGen has had compelling experimental and clinical data that suggest Colostrinin™ can support healthy brain ageing and cognition. In discussions with potential licensing partners, investors and healthcare practitioners however, initially, there has always been a degree of skepticism that a small dose of peptides given orally could lead to significant clinical effects. ReGen's recent work, which suggests that Colostrinin™ absorbed in the lining of the mouth triggers the production of other molecules that lead to the final outcome, should go a considerable way to removing this as an issue and lead to greater use of the product. 

Expert Opinion on Pharmacotherapy

An article by Professor Mike Stewart of the Open University, Milton Keynes, UK, reviewing the benefits of Colostrinin™ has also recently been published on-line in the journal Expert Opinion on Pharmacotherapy, October 2008. Summarising his article, Professor Stewart, a former scientific consultant to ReGen, said:

'Neurodegenerative illnesses such as Alzheimer's disease and their debilitating effects pose a major problem as their incidence increases. Given that Colostrinin™ has efficacy in counteracting neural degradation, stimulating neural growth, reducing oxidative stress, preventing beta-amyloid aggregation and prolonging the lifespan of mice prone to premature ageing it would seem to have much to commend its use as a nutraceutical in the early stages of cognitive decline in ageing humans and companion animals'.

Zolpidem

In June 2008, the Company announced that collaborators at Aston University, Birmingham UK had discovered new evidence of zolpidem's unique mode of action using pharmaco-magneto-encephalography (MEG) brain imaging. They found that non-functioning areas of the brain within the stroke damaged area of a patient were being kept in a dormant state by excessive slow wave activity that zolpidem reversed. This effect could not be reproduced with either a placebo or another sedative with a similar pharmacological action (zopiclone). ReGen has filed a new patent application around this important discovery.

Recent analysis of data from ReGen's first clinical study has established in patients with long-standing brain damage that the sublingual route of dosing is more consistent, faster in onset and more potent than existing tablets, characteristics that will greatly help patients to control the effect of dosing when they need to avoid sedation. More importantly, the trial also demonstrated that 2.5mg sublingually was non-sedative even when repeated, and since published reports have shown 2.5mg to be an effective dose in this new indication, it established a clear demarcation between ReGen's new indication and generic sedative formulations.

 

Currently, and with advice from internationally respected experts in stroke rehabilitation, ReGen has planned a further, double-blind clinical trial in the UK designed to demonstrate the efficacy of repeated doses of zolpidem after stroke. This trial will only proceed if an application for outside funding is successful. This trial, if positive, will prove unequivocally that zolpidem works in this new indication.

In the meantime, a study is ongoing at the University of Pretoria, examining the use of zolpidem to reverse neurodormancy after brain damage. Preliminary findings from this study were presented at the Asia Oceania Congress of Nuclear Medicine and Biology, Delhi, India, November, 2008.

In this prospective study, 40 patients with clinical and neurologically-confirmed brain damage due to various causes (mainly stroke and traumatic brain injury) were investigated by brain SPECT imaging before and after zolpidem. All patients underwent non-attenuation corrected Ceretec rest/zolpidem imaging. All testing was completed within a maximum period of a week. Three neuroimaging experts not directly involved in the study reviewed all of the images for each subject blinded to the treatment received. Concordance / discordance of brain SPECT and neurological assessment was determined. The results show that 72.5% of patients demonstrated an improvement in cerebral perfusion after zolpidem, which is significantly higher than the response rate based on clinical measurements only.

The findings of the MEG studies regarding the mechanism of the neurodormancy reversal and the preliminary findings of the Pretoria study were presented by Dr Ralf Clauss, a Scientific Advisor to ReGen, at the Ehrlich II Congress on 'Magic Bullets' in Nuremberg, Germany, at the beginning of October 2008.

There have been so many individual reports of a beneficial effect from zolpidem in a wide range of brain damage, from birth injury to trauma, stroke and others, that it is clear that zolpidem can help a considerable proportion of patients. The new Pretoria study suggests that the proportion of cases that might benefit from zolpidem could be much higher than expected from simple clinical responses. In some patients the benefit has been profound with recoveries of speech, continence, cognitive function and limb paralysis. Moreover, there has been no report of undue adverse effects other than the expected daytime sedation, all of which suggests that zolpidem should be tried in every case of brain injury.

OTCQX International 

On 14 July 2008 ReGen announced the listing of its American Depositary Receipts (ADRs) on the OTC market's prestigious tier, International PrimeQX. Pink OTC Markets Inc., is the leading electronic inter-dealer quotation system, trading technology and financial information provider for over-the-counter (OTC) securities. International Prime QX changed its name to OTCQX International in 2009.

 

People

 

Keith Corbin left the Board on 9 July 2008. He was the only person apart from myself who had been a Director of the Company since inception. During this period of time I found him to be a valuable source of advice and support and his comments were always perceptive at the Board meetings. We will miss him and wish him well with his demanding job running an International Trustee business. 

 

Nick Mills died unexpectedly in 2008. Nick was our veterinary consultant whose idea it was to develop a veterinary use for Colostrinin™. He completed a successful veterinary trial for the Company, upon which we hope to be able to capitalise.

 

Karl Kirwan died at the young age of 44 in Dublin in 2008. He was the prime mover behind us going to the OTCQX, to which we were finally admitted in July 2008.

 

Both Nick and Karl will be sadly missed and we wish their families well.

 

Summary

 

In the Report and Accounts for 2007 I commented that ReGen was getting to a stage where the nutraceutical product could take the Company into sustainable profitability. Indeed, up until quite recently it was our expectation that we would reach profitability in 2009. The credit crunch has had a severe impact on the business of our appointed and potential distributors and therefore on our development in the key markets of the USA and India. Consequently we now believe that we will not achieve sustainable profitability until 2010. Our losses until then, however, are expected to be significantly less than in 2008. In 2008 we lost £1.510m before tax for continuing operations compared with £2.586m in 2007, a reduction of £1.076m. We expect losses to decrease by an even larger amount in 2009 with sustainable profitability being achieved during 2010.

Percy W Lomax 

Executive Chairman

16 June 2009

Further information:

Percy Lomax ReGen Therapeutics Plc Tel: 020 7153 4920 Roland Cornish/Felicity Geidt Beaumont Cornish Limited Tel: 020 7628 3396

Nick Bealer/David Scott

Alexander David Securities Limited

Tel: 020 7448 9820

REGEN THERAPEUTICS PLC

Consolidated income statement for the year ended 31 December 2008 

		2008	2007
		£	£
		(Unaudited)	(Audited)
Continuing operations
Revenue		91,716	63,810
Cost of sales		20,447	24,042
		________	________
Gross Profit		71,269	39,768
Research and development costs		330,274	802,303
Other administrative costs		1,257,888	1,525,728
Impairment of intangible assets		-	348,562
Administrative expenses		1,588,162	2,676,593
		________	________
Operating loss		(1,516,893)	(2,636,825)
Finance income		10,308	56,534
Finance costs		(3,436)	(5,434)
		________	________
Loss before taxation		(1,510,021)	(2,585,725)
Taxation		80,590	168,517
		________	________
Loss after taxation for continuing activities		(1,429,431)	(2,417,208)
		________	________
Discontinued operations
(Loss)/profit after taxation from discontinued operations		(33,936)	32,134
		________	________
Loss after taxation for the year		(1,463,367)	(2,385,074)
		_________	_________
Basic and diluted loss per share	Note 7	(12.27)p	(25.71)p
Basic and diluted loss per share on continuing operations		(11.98p)	(26.07p)
Basic and diluted (loss)/profit per share on discontinued operations		(0.28p)	0.36p

  REGEN THERAPEUTICS PLC

Consolidated Statement Of Changes In Equity

for the year ended 31 December 2008

	Share capital £	Share premium £	Other reserves £	Retained earnings £	Total £
Audited
At 1 January 2007	5,992,251	11,991,836	265,745	(15,821,988)	2,427,844
Loss for the year	-	-	-	(2,385,074)	(2,385,074)
	________	________	________	________	________
Total recognised income and expense for the year	-	-	-	(2,385,074)	(2,385,074)
Net issue of share capital	331,584	1,977,558	-	-	2,309,142
Recognition of share based payments	-	-	-	88,184	88,184
	________	________	________	________	________
Balance at 31 December 2007	6,323,835	13,969,394	265,745	(18,118,878)	2,440,096
Unaudited
Loss for the year	-	-	-	(1,463,367)	(1,463,367)
	________	________	________	________	________
Total recognised income and expense for the year	-	-	-	(1,463,367)	(1,463,367)
Issue of share capital	281,168	395,970	-	-	677,138
Share issue costs	-	(218,151)	-	-	(218,151)
Recognition of share based payments	-	-	-	(95,532)	(95,532)
	________	________	________	________	________
Balance at 31 December 2008	6,605,003	14,147,213	265,745	(19,677,777)	1,340,184
	________	________	________	________	________

 

REGEN THERAPEUTICS PLC

Consolidated balance sheet at 31 December 2008 

		2008	2008	2007	2007
		£	£	£	£
		(Unaudited)	(Unaudited)	(Audited)	(Audited)
Non current assets
Property, plant and equipment			1,017		2,674
Intangible assets			1,759,250		1,946,559
			________		________
			1,760,267		1,949,233
Current assets
Inventories		28,571		6,649
Trade and other receivables		87,090		212,779
Tax receivable		80,590		145,833
Cash and cash equivalents		25,157		587,837
		________		________
Total current assets			221,408		953,098
			________		________
Total assets			1,981,675		2,902,331
			________		________
Liabilities
Current liabilities
Trade and other payables		489,699		311,636
Loans and borrowings		51,792		50,599
		________		________
Total current liabilities			541,491		362,235
Non current liabilities
Provisions			100,000		100,000
			________		________
Total liabilities			641,491		462,235
			________		________
Total net assets			1,340,184		2,440,096
			________		________
Equity
Share capital	Note 5		6,605,003		6,323,835
Share premium			14,147,213		13,969,394
Other reserves			265,745		265,745
Retained earnings			(19,677,777)		(18,118,878)
			________		________
Total equity			1,340,184		2,440,096
			________		________

 

REGEN THERAPEUTICS PLC

Consolidated cash flow statement for the year ended 31 December 2008 

	2008	2008	2007	2007
	£	£	£	£
	(Unaudited)	(Unaudited)	(Audited)	(Audited)
Loss after tax from continuing activities	(1,429,431)		(2,418,208)
(Loss)/profit after tax on discontinued activities	(33,936)		33,134
	________		________
Loss after tax for the financial year	(1,463,367)		(2,385,074)
Impairment of goodwill	-		348,562
Amortisation of intangible assets	298,256		34,910
Depreciation of property, plant and equipment	1,656		24,353
Share option (credit)/charge	(95,532)		88,184
Interest charged	7,830		8,581
Interest credited	(10,311)		(56,537)
Taxation credit	(80,590)		(168,517)
Taxation received	145,833		138,148
	________		________
Operating cash flows before movements in working capital and provisions	(1,196,225)		(1,967,390)
(Increase)/decrease in inventories	(21,922)		13,482
Decrease in receivables	125,689		16,739
Increase/(decrease) in payables	178,064		(247,956)
	________		________
Net cash outflow from operating activities	(914,394)		(2,185,125)
	________		________
Cash flows from investing activities
Interest received	10,311		56,537
Purchase of property, plant and equipment	-		(710)
Purchase of intangible assets	(110,947)		(69,630)
	________		________
Net cash used in investing activities	(100,636)		(13,803)
	________		________
Cash flows from financing activities
Proceeds from issue of share capital	677,138		2,486,875
Expenses paid on share issue	(218,151)		(177,733)
Interest paid	(7,830)		(8,581)
	________		________
Net cash from financing activities	451,157		2,300,561		_
	________		________
Net (decrease)/increase in cash and cash equivalents		(563,873)		101,633
Opening cash and cash equivalents		537,238		435,605
		________		________
Closing cash and cash equivalents Note 8		(26,635)		537,238
		________		________

  ReGen Therapeutics Plc

Notes forming part of the financial statements for the year ended 31 December 2008 

1 Basis of preparation

The consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (IFRSs and IFRIC interpretations) issued by the International Accounting Standards Board (IASB) as adopted by European Union ("adopted IFRSs") and with those parts of the Companies Act 1985 applicable to companies preparing their accounts under IFRS. 

The financial information contained in this announcement does not constitute statutory financial statements within the meaning of Section 240 of the Companies Act 1985. Whilst the financial information included in this announcement has been prepared in accordance with International Financial Reporting Standards (IFRS), this announcement itself does not contain sufficient financial information to comply with IFRS. A copy of the statutory financial statements for the year ended 31 December 2008 will be issued to shareholders prior to the Company's Annual General Meeting. The announcement has been agreed with the auditors and was approved by the Board of Directors on 16 June 2009. Whilst the auditors have not yet reported on the financial statements for the year ended 31 December 2008, they anticipate issuing an unqualified report which will not contain statements under section 237 (2) or (3) of the Companies Act 1985 but anticipate, however, including an explanatory paragraph dealing with a material uncertainty relating to going concern. The financial information for the year ended 31 December 2007 has been extracted from the statutory financial statements for that year, which have been filed with the Registrar of Companies. The audit report on those financial statements was unqualified and did not contain any statement under Sections 237 (2) or (3) of the Companies Act 1985. It did contain, however, an explanatory paragraph dealing with a material uncertainty relating to going concern

The directors do not recommend the payment of a dividend for the year.

2 Events after the balance sheet date

On 5 January 2009, the Company issued 350,000 ordinary shares of 0.01p each at a premium of 3.99p per share for a consideration of £14,000.

On 15 January 2009, the Company issued 400,000 ordinary shares of 0.01p each at a premium of 3.49p per share for a consideration of £14,000.

On 18 February 2009, the Company issued 2,171,834 ordinary shares of 0.01p each at a premium of 2.99p per share for a consideration of £65,155.

On 19 February 2009, the Company issued 1,751,666 ordinary shares of 0.01p each at a premium of 2.99p per share for a consideration of £52,550.

On 25 March 2009, the Company issued 700,000 ordinary shares of 0.01p each at a premium of 3.99p per share for a consideration of £28,000.

On 7 April 2009, the Company issued 2,149,332 ordinary shares of 0.01p each at a premium of 3.99p per share for a consideration of £64,480.

On 15 April 2009, the Company issued 800,000 ordinary shares of 0.01p each at a premium of 2.99p per share for a consideration of £24,000.

On 24 April 2009, the Company issued 2,000,000 ordinary shares of 0.01p each at a premium of 2.99p per share for a consideration of £60,000.

On 4 June 2009, the Company issued 1,000,000 ordinary shares of 0.01p each at a premium of 2.99p per share for a consideration of £30,000.

On 12 June 2009, the Company issued 500,000 ordinary shares of 0.01p each at a premium of 2.99p per share for a consideration of £15,000.

3 Going concern

The financial statements have been prepared on a going concern basis. However, the Group's ability to continue as a going concern is reliant upon successfully obtaining funds to finance ongoing development. In considering the appropriateness of this basis of preparation the directors have reviewed the Company's working capital forecasts. They believe that the funds raised recently, including new equity funds of £367,185 in aggregate raised between the balance sheet date and the date of approval of these financial statements, together with further options being considered and taken in conjunction with revenues from licensing, will be sufficient for the Group's purposes for a minimum of 12 months from 30 June 2009. If the Group was unable to secure sufficient funding to enable it to continue on a going concern basis then adjustments would be necessary to write down assets to their recoverable amounts, reclassify fixed assets and long term liabilities as current and provide for additional liabilities.

 

4. Accounting policies

The financial information has been prepared in accordance with the accounting policies adopted by the Group which are consistent with those adopted in the financial statements for the year ended 31 December 2007 as well as applying the following key accounting policies.

Business combinations

The consolidated financial statements incorporate the results of business combinations using the purchase method. In the consolidated balance sheet, the acquiree's identifiable assets, liabilities and contingent liabilities are initially recognised at their fair values at the acquisition date. The results of the acquired operations are included in the consolidated income statement from the date on which control is obtained.

Goodwill

Goodwill represents the excess of the cost of a business combination over the interest in the fair value of the identifiable assets, liabilities and contingent liabilities acquired. Cost comprises the fair values of assets given, liabilities assumed and equity instruments issued, plus any direct costs of acquisition.

Goodwill is capitalised as an intangible asset with any impairment in carrying value being charged to the consolidated income statement. Where the fair value of identifiable assets, liabilities and contingent liabilities exceed the fair value of consideration paid, the excess is credited in full to the consolidated income statement on the acquisition date. 

Research and development

Research expenditure is recognised in the income statement in the year in which it is incurred. Development expenditure is recognised in the income statement in the year in which it is incurred unless it meets the recognition criteria of IAS 38 "Intangible Assets". Regulatory and other uncertainties generally mean that such criteria are not met. Where, however the recognition criteria are met, intangible assets are capitalised and amortised on a straight-line basis over their useful economic lives from product launch. This policy is in line with industry practise.

5 Share Capital

On 26 March 2008, the Company issued 629,685 ordinary shares of 10p each at a premium of 22.5p per share for a consideration of £204,648.

On 27 March 2008, the Company issued 130,000 ordinary shares of 10p each at a premium of 22.5p per share for a consideration of £42,250.

On 27 March 2008, the Company issued 138,889 ordinary shares of 10p each at a premium of 26p per share for a consideration of £50,000 representing the draw down fees payable upon entering in to an agreement with Duke Holdings Corporation Limited ("Duke") under which Duke will make available to the Company an initial equity credit facility. The Company has an initial facility of £2,000,000, which is available for 24 months in two tranches of £1,000,000, with draw downs based on traded share volumes achieved by the Company.

On 17 April 2008, the Company issued 325,000 ordinary shares of 10p each at a premium of 13.8p per share for a consideration of £77,350.

On 12 August 2008, the Company issued 309,598 ordinary shares of 10p each at a premium of 6.15p per share for a consideration of £50,000.

On 13 August 2008, the Company issued 123,839 ordinary shares of 10p each at a premium of 6.15p per share for a consideration of £20,000.

On 15 September 2008, the Company issued 1,152,632 ordinary shares of 10p each with no premium per share for a consideration of £115,263.

On 6 October 2008 there was a resolution was passed at a General Meeting of the Company whereby a sub-division of Share Capital was effected so that every Existing Ordinary Share in issue was sub-divided and reclassified into one new ordinary share having a nominal value of 0.01 pence ("New Ordinary Shares") and one deferred B share having a nominal value of 9.99 pence ("Deferred B Share") (the "Sub-division").

The number of New Ordinary Shares in issue following the Sub-division equated to the number of Existing Ordinary Shares previously in issue. The Sub-division did not affect the rights attaching to the Existing Ordinary Shares, other than to alter their nominal value and, in particular, did not affect the voting rights of the holders of Existing Ordinary Shares.

As all Existing Ordinary Shares were sub-divided, each Shareholder's percentage holding in the issued share capital of the Company immediately before and after the implementation of the Sub-division remained unchanged.

On 27 October 2008, the Company issued 709,570 ordinary shares of 0.01p each at a premium of 6.43p per share for a consideration of £45,691.

On 27 October 2008, the Company issued 123,707 ordinary shares of 0.01p each at a premium of 9.99p per share for a consideration of £12,371. 

On 10 November 2008, the Company issued 305,252 ordinary shares of 0.01p each at a premium of 5.99p per share for a consideration of £18,315.

On 25 November 2008, the Company issued 350,000 ordinary shares of 0.01p each at a premium of 5.49p per share for a consideration of £19,250.

On 9 December 2008, the Company issued 550,000 ordinary shares of 0.01p each at a premium of 3.99p per share for a consideration of £22,000.

The issued shares rank pari passu with existing shares.

6 Discontinued operations

Due to the difficult market conditions and the very considerable competition in the UK Phase I/II clinical trials market the Board decided to close down the Guildford Clinical Pharmacology Unit Limited's offices in April 2008.

The results of the discontinued operations in this regard which have been included in the consolidated income statement, were as follows:

		2008 £	2007 £
Revenue		3,266	247,678
Expenses		37,202	215,544
		________	________
(Loss)/profit before taxation		(33,936)	33,134
Taxation		-	-
		________	________
Net loss attributable to discontinued operations		(33,936)	33,134
		________	________
Net cash flows attributable to operating activities		3,163	24,787
		________	________
Net cash flows attributable to investing activities		3	3
		________	________
Net cash flows attributable to financing activities		(4,394)	(3,147)
		________	________

7 Loss per share

		2008 £	2007 £
Numerator
Loss for the year		1,463,367	2,385,074
		________	________
Denominator
Weighted average number of share of 0.01p/10p		11,926,992	9,276,893
		________	________

The Company has instruments that could potentially dilute basic earnings per share in the future, but that have not been included in the calculation of diluted earnings per share because they are antidilutive for the periods presented.

8 Note supporting cash flow statement

Cash and cash equivalents comprises:
	2008	2007
	£	£
	(Unaudited)	(Audited)
Cash available on demand	7,682	18,579
Short-term deposits	17,475	569,258
	________	________
Cash and cash equivalents	25,157	587,837
Overdraft	(51,792)	(50,599)
	________	________
	(26,635)	537,238
	________	________

9 Taxation

		2008 £ (Unaudited)	2007 £ (Audited)
UK corporation tax credit in respect of current period		66,065	145,833
Adjustment in respect of prior years		14,525	22,684
		________	________
Total current tax credit		80,590	168,517
		________	________

The Group has unrecognised tax losses of approximately £13,500,000 (2007 - £12,500,000) for offset against future profits.

The rate of corporation tax changed to 28% with effect from April 2008.

The tax for the year differs from the standard rate of corporation tax in the UK. The differences are explained below:

		2008 £	2007 £
Loss before tax		1,543,957	2,553,591
		________	________
Loss at the standard rate of corporation tax in the UK of 28.5% (2007 - 30%)		440,028	766,077
Effects of:
Expenses not deductible for tax purposes		17,408	(165,192)
Expenditure qualifying for enhanced tax relief		46,990	-
Depreciation in excess of capital allowances		60,	-
Difference in tax rate applying to R&D tax credit		(58,703)	(35,621)
Unrecognised deferred tax		-	13,510
Tax losses for which no deferred tax asset recognised		(379,718)	(432,941)
Adjustment to prior year tax charge		14,525	22,684
		________	________
Total tax credit for the year		80,590	168,517
		________	________

The annual report and financial statements for the year ended 31 December 2008 will be sent to all shareholders in due course and copies will be available on the web site www.regentherapeutics.com and from the company's business address at 73 Watling Street, London, EC4M 9BJ.

ENDFR KGGMVDVRGLZM

---

Related Shares:

TILS.L